165 related articles for article (PubMed ID: 1975038)
1. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.
Yarchoan R; Pluda JM; Thomas RV; Mitsuya H; Brouwers P; Wyvill KM; Hartman N; Johns DG; Broder S
Lancet; 1990 Sep; 336(8714):526-9. PubMed ID: 1975038
[TBL] [Abstract][Full Text] [Related]
2. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
Rathbun RC; Martin ES
Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
[TBL] [Abstract][Full Text] [Related]
3. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
Cooley TP; Kunches LM; Saunders CA; Ritter JK; Perkins CJ; McLaren C; McCaffrey RP; Liebman HA
N Engl J Med; 1990 May; 322(19):1340-5. PubMed ID: 2139174
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
[TBL] [Abstract][Full Text] [Related]
5. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
Cooley TP; Kunches LM; Saunders CA; Perkins CJ; Kelley SL; McLaren C; McCaffrey RP; Liebman HA
Rev Infect Dis; 1990; 12 Suppl 5():S552-60. PubMed ID: 1974727
[TBL] [Abstract][Full Text] [Related]
6. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
[TBL] [Abstract][Full Text] [Related]
7. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.
Yarchoan R; Mitsuya H; Pluda JM; Marczyk KS; Thomas RV; Hartman NR; Brouwers P; Perno CF; Allain JP; Johns DG
Rev Infect Dis; 1990; 12 Suppl 5():S522-33. PubMed ID: 1974724
[TBL] [Abstract][Full Text] [Related]
8. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine.
Kieburtz KD; Seidlin M; Lambert JS; Dolin R; Reichman R; Valentine F
J Acquir Immune Defic Syndr (1988); 1992; 5(1):60-4. PubMed ID: 1346633
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.
Valentine FT; Seidlin M; Hochster H; Laverty M
Rev Infect Dis; 1990; 12 Suppl 5():S534-9. PubMed ID: 1974725
[TBL] [Abstract][Full Text] [Related]
10. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
[TBL] [Abstract][Full Text] [Related]
11. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
[TBL] [Abstract][Full Text] [Related]
12. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
Moyle GJ; Nelson MR; Hawkins D; Gazzard BG
Q J Med; 1993 Mar; 86(3):155-63. PubMed ID: 8387218
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.
Nguyen BY; Shay LE; Wyvill KM; Pluda JM; Brawley O; Cohen RB; Whitcup SM; Venzon DJ; Broder S; Yarchoan R
J Infect Dis; 1993 Oct; 168(4):810-7. PubMed ID: 8397267
[TBL] [Abstract][Full Text] [Related]
14. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.
Yarchoan R; Mitsuya H; Thomas RV; Pluda JM; Hartman NR; Perno CF; Marczyk KS; Allain JP; Johns DG; Broder S
Science; 1989 Jul; 245(4916):412-5. PubMed ID: 2502840
[TBL] [Abstract][Full Text] [Related]
15. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
Spruance SL; Pavia AT; Peterson D; Berry A; Pollard R; Patterson TF; Frank I; Remick SC; Thompson M; MacArthur RD; Morey GE; Ramirez-Ronda CH; Bernstein BM; Sweet DE; Crane L; Peterson EA; Pachucki CT; Green SL; Brand J; Rios A; Dunkle LM; Cross A; Brown MJ; Ingraham P; Gugliotti R; Schindzielorz AH; Smaldone L
Ann Intern Med; 1994 Mar; 120(5):360-8. PubMed ID: 7905722
[TBL] [Abstract][Full Text] [Related]
16. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients.
Rozencweig M; McLaren C; Beltangady M; Ritter J; Canetta R; Schacter L; Kelley S; Nicaise C; Smaldone L; Dunkle L
Rev Infect Dis; 1990; 12 Suppl 5():S570-5. PubMed ID: 2166965
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI).
Reddy MM; McKinley GF; Grieco MH
J Clin Lab Anal; 1991; 5(6):396-8. PubMed ID: 1774603
[TBL] [Abstract][Full Text] [Related]
18. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
Kahn JO; Lagakos SW; Richman DD; Cross A; Pettinelli C; Liou SH; Brown M; Volberding PA; Crumpacker CS; Beall G
N Engl J Med; 1992 Aug; 327(9):581-7. PubMed ID: 1353607
[TBL] [Abstract][Full Text] [Related]
19. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex.
Dolin R; Lambert JS; Morse GD; Reichman RC; Plank CS; Reid J; Knupp C; McLaren C; Pettinelli C
Rev Infect Dis; 1990; 12 Suppl 5():S540-9; discussion S549-51. PubMed ID: 1974726
[TBL] [Abstract][Full Text] [Related]
20. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
Reichman RC; Tejani N; Lambert JL; Strussenberg J; Bonnez W; Blumberg B; Epstein L; Dolin R
Antiviral Res; 1993 Apr; 20(4):267-77. PubMed ID: 8097906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
